Patent Extensions Cost US $3.5 Billion in Delayed Generic Savings
Delayed Generic drug entry Cost US Billions, Study Finds
WASHINGTON D.C. – A new study published in JAMA Health Forum reveals that strategic patenting practices by brand-name drug manufacturers led to an estimated $3.5 billion in excess spending on four top-selling drugs over a two-year period.the research highlights how ”patent thickets” – a dense web of overlapping patents – delay the availability of lower-cost generic alternatives, impacting both commercial insurance holders and Medicare beneficiaries.
The study focused on four widely prescribed medications: imatinib (Gleevec, used to treat leukemia), glatiramer (Copaxone, for multiple sclerosis), celecoxib (Celebrex, a pain reliever), and bimatoprost (Lumigan, for glaucoma).Researchers compared actual drug spending with a modeled scenario where generic competition had launched promptly after the expiration of the original patents.
The findings indicate that the largest cost savings from timely generic entry occur in the initial year after launch, when brand-name drugs still maintain a meaningful market share. While savings continue to accrue over time, the rate of reduction slows as generic competition stabilizes.
The Problem of Patent Thickets
brand-name drug companies frequently employ a strategy known as creating a “patent thicket.” This involves filing numerous patents, not just on the core drug molecule, but also on minor variations like delivery methods, formulations, or manufacturing processes. These overlapping patents create legal hurdles for generic manufacturers, delaying their ability to enter the market.
“Essentially,it’s a legal strategy to extend a monopoly beyond the original patent’s lifespan,” explains Dr. Jennifer Chen, a health economist specializing in pharmaceutical pricing.”While patent protection is vital to incentivize innovation, these ‘thickets’ ofen go beyond legitimate innovation and serve primarily to block competition.”
Study Details & findings
The researchers utilized data from a commercial claims database and a sample of Medicare beneficiaries (Parts A,B,and D) to analyze monthly drug spending from 2011 to 2021. They modeled two scenarios:
Observed Spending: Actual drug spending with the delays caused by patent thickets.
Counterfactual Spending: Projected spending if generic competition had launched immediately after the key patent expiration.
Here’s a breakdown of the estimated excess spending for each drug:
| Drug (Brand Name) | Generic Equivalent | Estimated Excess Spending (2 Years) |
|---|---|---|
| Imatinib (Gleevec) | Imatinib | $1.47 billion |
| Glatiramer (Copaxone) | Glatiramer Acetate | $1.14 billion |
| Celecoxib (Celebrex) | Celecoxib | $648 million |
| Bimatoprost (lumigan) | Bimatoprost | $279 million |
| Total | $3.54 billion |
Key Findings:
Early Savings are Largest: the moast significant cost reductions occurred in the first year after generic entry.
Market Share Matters: Brand-name drugs retained substantial market share even after generic launch, contributing to excess spending.
* Cumulative Savings Grow: While the rate of reduction